PL8177 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
97. Ulcerative colitis
Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05466890 (ClinicalTrials.gov) | September 15, 2022 | 25/5/2022 | Phase 2a To Evaluate PL-8177 in Subjects With Active Ulcerative Colitis (UC) | Phase 2a, Double-Blind, Randomized Adaptive Design, Placebo-Controlled, Parallel Group Study to Evaluate the Safety, Tolerability, Efficacy, PK and Biomarkers With Oral Colon Delivery PL8177 in Adult Subjects With Active Ulcerative Colitis | Ulcerative Colitis;Ulcerative Colitis Acute;Ulcerative;Ulcerative Colitis Flare | Drug: PL8177 Placebo;Drug: PL8177 | Palatin Technologies, Inc | NULL | Recruiting | 18 Years | 75 Years | All | 28 | Phase 2 | United States |